Selective PPARδ agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study

Peroxisome proliferator-activated receptor-delta (PPARdelta) activation results in upregulation of genes associated with skeletal muscle fatty acid oxidation and mitochondrial uncoupling. However, direct, noninvasive assessment of lipid metabolism and mitochondrial energy coupling in skeletal muscle following PPARdelta stimulation has not been examined. Therefore, in this study we examined the response of a selective PPARdelta agonist (GW610742X at 5 or 100 mg.kg(-1).day(-1) for 8 days) on skeletal-muscle lipid metabolism and mitochondrial coupling efficiency in rats by using in vivo magnetic resonance spectroscopy (MRS). There was a decrease in the intramyocellular lipid-to-total creatine ratio as assessed by in vivo (1)H-MRS in soleus and tibialis anterior muscles by day 7 (reduced by 49 and 46%, respectively; P < 0.01) at the high dose. Following the (1)H-MRS experiment (day 8), [1-(13)C]glucose was administered to conscious rats to assess metabolism in the soleus muscle. The relative fat-vs.-carbohydrate oxidation rate increased in a dose-dependent manner (increased by 52 and 93% in the 5 and 100 mg.kg(-1).day(-1) groups, respectively; P < 0.05). In separate experiments where mitochondrial coupling was assessed in vivo (day 7), (31)P-MRS was used to measure hindlimb ATP synthesis and (13)C-MRS was used to measure the hindlimb tricarboxylic acid cycle flux (V(tca)). There was no alteration, at either dose, in mitochondrial coupling efficiency measured as the ratio of unidirectional ATP synthesis flux to V(tca). Soleus muscle GLUT4 expression was decreased by twofold, whereas pyruvate dehydrogenase kinase 4, carnitine palmitoyl transferase 1a, and uncoupling protein 2 and 3 expression was increased by two- to threefold at the high dose (P < 0.05). In summary, these are the first noninvasive measurements illustrating a selective PPARdelta-mediated decrease in muscle lipid content that was consistent with a shift in metabolic substrate utilization from carbohydrate to lipid. However, the mitochondrial-energy coupling efficiency was not altered in the presence of increased uncoupling protein expression.

[1]  K. Tsintzas,et al.  PPARδ agonism induces a change in fuel metabolism and activation of an atrophy programme, but does not impair mitochondrial function in rat skeletal muscle , 2007 .

[2]  C. Doe,et al.  PPARδ Activation Normalizes Cardiac Substrate Metabolism and Reduces Right Ventricular Hypertrophy in Congestive Heart Failure , 2007 .

[3]  T. Willson,et al.  Triglyceride:High-Density Lipoprotein Cholesterol Effects in Healthy Subjects Administered a Peroxisome Proliferator Activated Receptor &dgr; Agonist , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[4]  W. Waldhäusl,et al.  Activation of PPAR-δ in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids , 2006, Diabetologia.

[5]  Jerrold M. Olefsky,et al.  PPARδ regulates glucose metabolism and insulin sensitivity , 2006 .

[6]  J. Berger,et al.  PPARs: therapeutic targets for metabolic disease. , 2005, Trends in pharmacological sciences.

[7]  B. Staels,et al.  Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1 Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400400-JLR200 , 2005, Journal of Lipid Research.

[8]  W. Bao,et al.  Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. , 2005, Diabetes.

[9]  R. Evans,et al.  Regulation of Muscle Fiber Type and Running Endurance by PPARδ , 2004, PLoS biology.

[10]  G. Barish,et al.  PPARs and the complex journey to obesity , 2004, Nature Medicine.

[11]  Johan Auwerx,et al.  Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Muscat,et al.  The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. , 2003, Molecular endocrinology.

[13]  W. Bao,et al.  Activation of Peroxisome Proliferator–Activated Receptor-&agr; Protects the Heart From Ischemia/Reperfusion Injury , 2003, Circulation.

[14]  Jourdan J. Pouliot,et al.  development and , 2019 .

[15]  R. Evans,et al.  Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity , 2003, Cell.

[16]  S. Sarkar,et al.  Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study. , 2003, Metabolism: clinical and experimental.

[17]  W. Kraus,et al.  Fatty Acid Homeostasis and Induction of Lipid Regulatory Genes in Skeletal Muscles of Peroxisome Proliferator-activated Receptor (PPAR) α Knock-out Mice , 2002, The Journal of Biological Chemistry.

[18]  S. Sarkar,et al.  Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study. , 2002, Diabetes.

[19]  H. Itoh,et al.  Up-regulation of uncoupling protein 3 gene expression by fatty acids and agonists for PPARs in L6 myotubes. , 2001, Endocrinology.

[20]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Dufour,et al.  13C/31P NMR Assessment of Mitochondrial Energy Coupling in Skeletal Muscle of Awake Fed and Fasted Rats , 2000, The Journal of Biological Chemistry.

[22]  S. Dufour,et al.  Assessment of mitochondrial energy coupling in vivo by 13C/31P NMR. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Klingenberg,et al.  H+ transport by uncoupling protein (UCP-1) is dependent on a histidine pair, absent in UCP-2 and UCP-3. , 1998, Biochemistry.

[24]  G. Shulman,et al.  13C and 31P NMR Studies on the Effects of Increased Plasma Free Fatty Acids on Intramuscular Glucose Metabolism in the Awake Rat* , 1997, The Journal of Biological Chemistry.

[25]  C Boesch,et al.  In vivo determination of intra‐myocellular lipids in human muscle by means of localized 1H‐MR‐spectroscopy , 1997, Magnetic resonance in medicine.

[26]  F Schick,et al.  Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: Two lipid compartments in muscle tissue , 1993, Magnetic resonance in medicine.

[27]  H. S. Belding,et al.  An analysis of the relation between basal metabolism and summated tissue respiration in the rat. I. The post‐pubertal albino rat , 1939 .

[28]  C. Doe,et al.  PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure. , 2007, Journal of cardiovascular pharmacology.

[29]  K. Tsintzas,et al.  PPARdelta agonism induces a change in fuel metabolism and activation of an atrophy programme, but does not impair mitochondrial function in rat skeletal muscle. , 2007, The Journal of physiology.

[30]  A. Hevener,et al.  PPARdelta regulates glucose metabolism and insulin sensitivity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Auwerx,et al.  Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G. Muscat,et al.  The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. , 2003, Molecular endocrinology.

[33]  R. Evans,et al.  Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. , 2003, Cell.

[34]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[35]  J. Himms-Hagen,et al.  Brown adipose tissue thermogenesis and obesity. , 1989, Progress in lipid research.